Cartherics

About

Cartherics develops allogeneic iPSC-derived CAR-NK and CAR-T immunotherapies from cord blood, genetically engineering safe-harbor sites to enhance NK/T cells; lead CTH-401 targets TAG-72 and advances to clinical trial.

Mission

Cartherics develops cell-based immunotherapies, including CAR-NK and CAR-T products, using an allogeneic off-the-shelf iPSC platform derived from donated cord blood. The company genetically engineers iPSCs at specific “safe harbour” genomic sites to enhance the function of differentiated NK, T and other immune cells. Its lead product, CTH-401, is a CAR-NK therapy directed against the tumour antigen TAG-72 and includes deletions of two genes associated with immunosuppression. Cartherics has shown CTH-401 effectively kills ovarian cancer cells in tissue culture and animal models, and plans to initiate the first clinical trial next year. The recent financing will support the CTH-401 clinical trial and allow the company to expand its pipeline into other diseases. The company is privately held and headquartered in Melbourne, Australia.

Quick Facts